Iniparib

Phase 2Small molecule

Sanofi

Iniparib is one of 74 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Breast CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Trodelvy

Gilead

Preclinical

37 3

Halaven

Eisai

Preclinical

38 4

Tykerb

GSK

Preclinical

80 5

Adriamycin

GGynecologic Oncology Group

Preclinical

87 6

Avastin

BBio-Thera Solutions

Preclinical

153 7

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 8

Prolia

Amgen

Preclinical

14 9

Gemzar

GGynecologic Oncology Group

DATROWAY

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer6 trials

A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Completed· Sanofi logo

Sanofi·Phase 2·NCT01173497·44 enrolled

A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer

Completed· Sanofi logo

Sanofi·Phase 2·NCT00540358·123 enrolled

A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

Completed· Sanofi logo

Sanofi·Phase 3·NCT00938652·519 enrolled

Show 3 more trials

An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer

No longer available· Sanofi logo

Sanofi··NCT01130259

Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer

Completed· Sanofi logo

Sanofi·Phase 2·NCT01045304·163 enrolled

Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients

Completed· Sanofi logo

Sanofi·Phase 2·NCT01204125·141 enrolled

Non-Small Cell Lung Cancer1 trial

SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer

Completed· Sanofi logo

Sanofi·Phase 2·NCT01086254·119 enrolled

Advanced Epithelial Ovarian1 trial

Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Completed· Sanofi logo

Sanofi·Phase 2·NCT00677079·12 enrolled

Clinical Trial1 trial

Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

Completed· Sanofi logo

Sanofi·Phase 3·NCT01593228·37 enrolled

Patients With Advanced Solid Tumors1 trial

Safety and Pharmacokinetics of SAR240550 (BSI-201) Twice Weekly in Patients With Advanced Solid Tumors

Completed· Sanofi logo

Sanofi·Phase 1·NCT01213381·18 enrolled

2 more indications

Solid Tumors1 trial

A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors

Completed· Sanofi logo

Sanofi·Phase 1·NCT01455532·59 enrolled

Unspecified1 trial

An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi)

Completed· Sanofi logo

Sanofi·Phase 1·NCT01161836·7 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Iniparib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Iniparib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Iniparib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Sanofi

Iniparib

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer6 trials

Non-Small Cell Lung Cancer1 trial

Advanced Epithelial Ovarian1 trial

Clinical Trial1 trial

Patients With Advanced Solid Tumors1 trial

Solid Tumors1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News